RxDoctor Payments Data

Dawn Bodnar, MD

Cardiovascular Disease · Omaha, NENPI 1164475729

Payments from drug & device makers

$681in general payments, 2019–2025

Across 29 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$230
  • Novartis$122
  • Pfizer$78
  • Bridgebio Pharma, Inc.$51
  • Saranas, Inc.$46
  • Scpharmaceuticals Inc.$40
  • plus $114 from 5 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$681 in reported general payments places this provider in the 20th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$113,228
Medicare patients
1,234
Services billed
2,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$475,044
EntrestoSacubitril/Valsartan195$199,814
XareltoRivaroxaban70$79,151
JardianceEmpagliflozin57$65,981
Repatha SureclickEvolocumab56$51,725
FarxigaDapagliflozin Propanediol34$24,859
BrilintaTicagrelor39$20,854
MultaqDronedarone Hcl14$14,446
Praluent PenAlirocumab18$12,996
Metoprolol Succinate736$9,897
VascepaIcosapent Ethyl11$7,311
Atorvastatin Calcium605$5,898
Potassium Chloride292$5,708
Ranolazine ErRanolazine69$4,744
Ezetimibe178$3,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$475,044437 claims
NovartisEntresto$122$199,814195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →